A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 981-983

  O'Byrne, K J ^a   Philip, P A ^a   Propper, D J ^a   Braybrooke, J P ^a   Saunders, M P ^a   Bates, N P ^a   Taylor, M A ^a   Madigan, D ^a   Ganesan, T S ^a   Talbot, D C ^a   Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Folinic acid; Hydroxyurea; Modulation

Indexed keywords

DEOXYRIBONUCLEOTIDE; DNA; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DOSE CALCULATION; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032849643     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008330302535     Document Type: Article

References (15)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. Mead GM. Raltitrexed, a new drug for advanced colorectal cancer. Lancet 1996; 347: 1568-9.
3. Kobayashi S, Hoshino T. Combined cytotoxic effect of low-dose 5-fluorouracil and hydroxyurea on 9L cells in vitro. Cancer Res 1983; 43: 5309-13.
4. Matei D, Hagag N, Madajewicz S et al. Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma. Cancer 1995; 76: 1330-5.
5. Philip P, Kaklamanis L, Carmichael J et al. The influence of high-dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUDR) by human bone marrow and tumour cells in vivo. Br J Cancer 1993: 67: 644-9.
6. de Gramont A, Bosset J-F, Milan C et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-15.
7. Muggia FM, Moran RG. Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea. Semin Oncol 1992; 19 (3, Suppl 9): 90-3.
8. Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administered by continuous infusion. Cancer 1980; 46: 455-62.
9. Di Costanzo FD, El-Taani H, Parriani D et al. Hydroxyurea may increase the activity of fluorouracil plus folinic acid in advanced gastrointestinal cancer: Phase II study. Cancer Invest 1996; 14: 234-8.
10. Gebbia V, Valenza R, Testa A et al. Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinoma. Am J Clin Oncol 1994; 17: 485-9.
11. de Gramont A, Louvet C, Bennamoun M et al. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J Inf Chemo 1996; 6: 97-101.
12. O'Byrne KJ, Philip P, Saunders M et al. Modulation of 5-fluorouracil and folinic acid with hydroxyurea in the treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 172.
13. Raschko JW, Akman SA, Leong LA et al. Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemother Pharmacol 1994; 35: 161-4.
14. Cheng Y-C, Nakayama K. Effects of 5-fluoro-2-deoxyuridine on DNA metabolism in HeLa cells. Mol Pharmacol 1983; 23: 171-4.
15. Spears CP, Gustavsson BG, Berne M et al. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988; 48: 5894-900.